Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company is based in Brooklyn, New York.
IPO Year: 2021
Exchange: AMEX
Website: brooklynitx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/29/2021 | $9.00 | Overweight | Cantor Fitzgerald |
| 10/6/2021 | $20.00 | Buy | Maxim Group |
Cantor Fitzgerald initiated coverage of Brooklyn with a rating of Overweight and set a new price target of $9.00
Maxim Group initiated coverage of Brooklyn ImmunoTherapeutics with a rating of Buy and set a new price target of $20.00
SC 13G/A - Eterna Therapeutics Inc. (0000748592) (Subject)
SC 13G/A - Eterna Therapeutics Inc. (0000748592) (Subject)
SC 13D/A - Eterna Therapeutics Inc. (0000748592) (Subject)
SC 13G - Eterna Therapeutics Inc. (0000748592) (Subject)
SC 13G/A - Eterna Therapeutics Inc. (0000748592) (Subject)
SC 13D/A - Eterna Therapeutics Inc. (0000748592) (Subject)
SC 13G - Eterna Therapeutics Inc. (0000748592) (Subject)
SC 13D/A - Eterna Therapeutics Inc. (0000748592) (Subject)
SC 13G/A - Eterna Therapeutics Inc. (0000748592) (Subject)
SC 13G/A - Eterna Therapeutics Inc. (0000748592) (Subject)
Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: National Funds Ticker Distribution Declaration- 5/1/2025 Ex-Date- 5/15/2025 Record- 5/15/2025 Payable- 6/2/2025 Ticker Distribution Change From Prior Distribution BlackRock Municipal Income Quality Trust* BYM $0.055500 - BlackRock Long-Term Municipal Advantage Trust* BTA $0.049500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Trust* BFK $0.050000 - BlackRock Investment Quality Municipal Trust, Inc.* BKN $0.057000 - BlackRock Municipal Incom
Today, BlackRock Resources & Commodities Strategy Trust (NYSE:BCX), BlackRock Enhanced Equity Dividend Trust (NYSE:BDJ), BlackRock Energy and Resources Trust (NYSE:BGR), BlackRock Enhanced International Dividend Trust (NYSE:BGY), BlackRock Health Sciences Trust (NYSE:BME), BlackRock Health Sciences Term Trust (NYSE:BMEZ), BlackRock Enhanced Global Dividend Trust (NYSE:BOE), BlackRock Utilities, Infrastructure & Power Opportunities Trust (NYSE:BUI), BlackRock Enhanced Large Cap Core Fund, Inc. (NYSE:CII), BlackRock Science and Technology Trust (NYSE:BST), BlackRock Science and Technology Term Trust (NYSE:BSTZ), BlackRock Technology and Private Equity Term Trust (NYSE:BTX), BlackRock Capital
BlackRock Advisors, LLC announced today the results of the Special Shareholder Meeting of the BlackRock Technology and Private Equity Term Trust (NYSE:BTX) (the "Trust"). Shareholders have approved (i) an amendment to the Trust's fundamental investment restriction with respect to industry concentration to allow the Trust to concentrate its investments in companies operating in one or more industries within the technology group of industries and (ii) a change in the Trust's diversification status under the Investment Company Act of 1940 from diversified to non-diversified. About BlackRock BlackRock's purpose is to help more and more people experience financial well-being. As a fiduciary to
Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: National Funds Ticker Distribution Declaration- 4/1/2025 Ex-Date- 4/15/2025 Record- 4/15/2025 Payable- 5/1/2025 Ticker Distribution Change From Prior Distribution BlackRock Municipal Income Quality Trust* BYM $0.055500 - BlackRock Long-Term Municipal Advantage Trust* BTA $0.049500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Trust* BFK $0.050000 - BlackRock Investment Quality Municipal Trust, Inc.* BKN $0.057000 - BlackRock Municip
Today, BlackRock Resources & Commodities Strategy Trust (NYSE:BCX), BlackRock Enhanced Equity Dividend Trust (NYSE:BDJ), BlackRock Energy and Resources Trust (NYSE:BGR), BlackRock Enhanced International Dividend Trust (NYSE:BGY), BlackRock Health Sciences Trust (NYSE:BME), BlackRock Health Sciences Term Trust (NYSE:BMEZ), BlackRock Enhanced Global Dividend Trust (NYSE:BOE), BlackRock Utilities, Infrastructure & Power Opportunities Trust (NYSE:BUI), BlackRock Enhanced Large Cap Core Fund, Inc. (NYSE:CII), BlackRock Science and Technology Trust (NYSE:BST), BlackRock Science and Technology Term Trust (NYSE:BSTZ), BlackRock Technology and Private Equity Term Trust (NYSE:BTX), BlackRock Capital
Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: National Funds Ticker Distribution Declaration- 3/3/2025 Ex-Date- 3/14/2025 Record- 3/14/2025 Payable- 4/1/2025 Ticker Distribution Change From Prior Distribution BlackRock Municipal Income Quality Trust* BYM $0.055500 - BlackRock Long-Term Municipal Advantage Trust* BTA $0.049500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Trust* BFK $0.050000 - BlackRock
Today, BlackRock Resources & Commodities Strategy Trust (NYSE:BCX), BlackRock Enhanced Equity Dividend Trust (NYSE:BDJ), BlackRock Energy and Resources Trust (NYSE:BGR), BlackRock Enhanced International Dividend Trust (NYSE:BGY), BlackRock Health Sciences Trust (NYSE:BME), BlackRock Health Sciences Term Trust (NYSE:BMEZ), BlackRock Enhanced Global Dividend Trust (NYSE:BOE), BlackRock Utilities, Infrastructure & Power Opportunities Trust (NYSE:BUI), BlackRock Enhanced Large Cap Core Fund, Inc. (NYSE:CII), BlackRock Science and Technology Trust (NYSE:BST), BlackRock Science and Technology Term Trust (NYSE:BSTZ), BlackRock Technology and Private Equity Term Trust (NYSE:BTX), BlackRock Capital
The BlackRock closed-end funds listed below (each, a "Fund" and collectively, the "Funds") announced today the renewal of their discount management programs (each, a "Program" and collectively, the "Programs"). Under the terms of each Fund's Program, each Fund intends to offer to repurchase a portion of its common shares via tender offer if certain conditions are met during the specified time period, as detailed below. BlackRock Closed-End Funds Renewing their Discount Management Programs Fund Name Ticker BlackRock Capital Allocation Term Trust BCAT BlackRock ESG Capital Allocation Term Trust ECAT BlackRock Science and Technology Term Tr
New name reflects Company focus on leveraging exclusively in-licensed foundational mRNA cell engineering patent portfolio The Eterna corporate mission is to realize the potential of cell engineering to provide patients with transformational new medicines Company's shares to trade under new ticker symbol "ERNA" starting on October 17, 2022, and a one-for-twenty share consolidation will become effective on that date SAN DIEGO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn" or the "Company"), today announces that it is changing its name to Eterna Therapeutics Inc. ("Eterna") to reflect its focus on developing advanced therapies using its extens
SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn" or the "Company") today announces results from the INSPIRE phase 2 trial of IRX-2, a multi-cytokine biologic immunotherapy, in patients with newly diagnosed stage II, III, or IVA squamous cell carcinoma of the oral cavity. The primary endpoint of the study was to estimate 2-year Event-Free Survival (EFS) with key secondary endpoints of Overall Survival (OS) and safety of IRX-2. One hundred and fifty patients were enrolled in the study. At two years of follow-up in the intention-to-treat (ITT, n=105) population the median EFS was 48.3 months and was not reached in the control arm (Hazard
DEFA14A - BlackRock Technology & Private Equity Term Trust (0001836057) (Filer)
N-CEN - BlackRock Technology & Private Equity Term Trust (0001836057) (Filer)
DEF 14A - BlackRock Technology & Private Equity Term Trust (0001836057) (Filer)
N-CSR - BlackRock Technology & Private Equity Term Trust (0001836057) (Filer)
8-K - Eterna Therapeutics Inc. (0000748592) (Filer)
424B3 - Eterna Therapeutics Inc. (0000748592) (Filer)
EFFECT - Eterna Therapeutics Inc. (0000748592) (Filer)
8-K - Eterna Therapeutics Inc. (0000748592) (Filer)
S-8 - Eterna Therapeutics Inc. (0000748592) (Filer)
S-3 - Eterna Therapeutics Inc. (0000748592) (Filer)
3 - Eterna Therapeutics Inc. (0000748592) (Issuer)
4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
3 - Eterna Therapeutics Inc. (0000748592) (Issuer)
4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
3 - Eterna Therapeutics Inc. (0000748592) (Issuer)
3 - Eterna Therapeutics Inc. (0000748592) (Issuer)
4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn" or the "Company"), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating patients with cancer, blood disorders, and monogenic diseases, today announced the appointment of Matt Angel, Ph.D., Co-Founder, Chairman, and CEO of Factor Bioscience Inc., as Interim Chief Executive Officer and President. He will replace Howard J. Federoff, M.D., Ph.D., Chief Executive Officer and President, who departs to focus on building a new venture. The Company also announces the appointment of Andrew Jackson as Chief
Erin Enright and Alfonso "Chito" Zulueta Appointed to Board of Directors New Board Members Bring Skills and Experience Aligned with the Company's Strategy Per Wold-Olsen Named Chairman of the Board David Stack and Joe Zakrzewski to Retire from the Board Actions Reflect Company and Board's Commitment to Ongoing Refreshment and Enhancement DUBLIN, Ireland and BRIDGEWATER, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced a series of appointments and leadership changes to its Board of Directors, including: Appointment of Erin Enright and Alfonso "Chito" Zulueta to the Board, effective immediately. Ms. Enright and Mr. Zulueta will sta
NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces the appointment of two new members of the Company's Board of Directors. Erin S. Enright has served on multiple Boards of Directors, including within the medical and life sciences arenas, such as Keystone Dental (serving as Audit Committee Chair), Medical Facilities Corporation (serving as Audit and Investment Committee Chair), and Dynatronics Corporation (serving on the Audit, Compensati
NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces the appointment of Susan McClatchey as Vice President, Head of Quality. "We are aggressively preparing to handle what we believe will be a rapid ramp-up of drug development activities through our gene editing/cell therapy platform, which will require specialized resources including quality assurance," commented Howard J. Federoff, M.D., Ph.D, Brooklyn's President and Chief Executive Offi
NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced the appointment of Roger Sidhu, M.D. as its Chief Medical Officer, effective September 20, 2021. "Roger's extensive R&D experience, including many years in late-stage clinical development involving a wide array of treatment modalities for hematologic malignancies and solid tumors, brings him to Brooklyn at an inflection point where his insight and understanding will help guide us to the
NEW YORK, July 13, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced the appointment of Jay Sial as its Chief Administrative Officer, effective July 15, 2021. "Jay has a long and impressive history managing the finances of multiple health systems and hospitals and leading the financial transformation of complex organizations through prudent management and strategic activities, including fundraising, business development and facilities management. We are tru
BROOKLYN, N.Y., June 08, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic disorders, today announced the appointment of Kevin A. D’Amour, Ph.D. as its Chief Scientific Officer. Dr. D’Amour joins Brooklyn from ViaCyte, Inc., a private, clinical stage company developing stem cell-based therapy for type 1 and insulin-dependent type 2 diabetes, where he most recently served as Chief Scientific Officer. He holds more than 100 U.S. and international patents and has been wide
Brooklyn ImmunoTherapeutics, Inc. (NYSE:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer and blood disorders, today announced the appointment of Michael Andreeff, M.D., Ph.D. to Brooklyn's Scientific Advisory Board, effective May 21, 2021. Dr. Andreeff currently serves as a Professor of Medicine at MD Anderson Cancer Center where he holds the Paul and Mary Haas Chair in Genetics and is the Chief of Molecular Hematology and Therapy. Dr. Andreeff received his M.D. and Ph.D. from the University of Heidelberg, Germany, and additional training at Memorial Sloan Kettering Cancer Cent
Brooklyn ImmunoTherapeutics, Inc. (NYSE:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders and monogenic diseases, today announced the appointment of Erich Mohr, Ph.D., ICD.D. to Brooklyn's Board of Directors, effective May 7, 2021. "Dr. Erich Mohr's distinguished career as a leader of life sciences companies, as well as in academic research, will serve as an important resource to Brooklyn," said Howard J. Federoff, M.D., Ph.D. Brooklyn ImmunoTherapeutics' Chief Executive Officer and President. "Dr. Mohr has a proven track record of creating value both as a Board
Brooklyn ImmunoTherapeutics, Inc. (NYSE:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, today announced the appointment of Matthew During, M.D., Ph.D. to the Company's Scientific Advisory Board, effective April 26, 2021. Dr. During is a Harvard, MIT and Yale trained neuroscientist. He has served for 9 years as a member of the faculty of Yale as Professor of Neurosurgery, and as a Professor at Thomas Jefferson, Cornell, and Ohio State Universities. Dr. During was a pioneer in the use of viral vectors for neurological disorders, and was the first to carry out gene transfer into the brain of a
Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: National Funds Ticker Distribution Declaration- 5/1/2025 Ex-Date- 5/15/2025 Record- 5/15/2025 Payable- 6/2/2025 Ticker Distribution Change From Prior Distribution BlackRock Municipal Income Quality Trust* BYM $0.055500 - BlackRock Long-Term Municipal Advantage Trust* BTA $0.049500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Trust* BFK $0.050000 - BlackRock Investment Quality Municipal Trust, Inc.* BKN $0.057000 - BlackRock Municipal Incom
Today, BlackRock Resources & Commodities Strategy Trust (NYSE:BCX), BlackRock Enhanced Equity Dividend Trust (NYSE:BDJ), BlackRock Energy and Resources Trust (NYSE:BGR), BlackRock Enhanced International Dividend Trust (NYSE:BGY), BlackRock Health Sciences Trust (NYSE:BME), BlackRock Health Sciences Term Trust (NYSE:BMEZ), BlackRock Enhanced Global Dividend Trust (NYSE:BOE), BlackRock Utilities, Infrastructure & Power Opportunities Trust (NYSE:BUI), BlackRock Enhanced Large Cap Core Fund, Inc. (NYSE:CII), BlackRock Science and Technology Trust (NYSE:BST), BlackRock Science and Technology Term Trust (NYSE:BSTZ), BlackRock Technology and Private Equity Term Trust (NYSE:BTX), BlackRock Capital
Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: National Funds Ticker Distribution Declaration- 4/1/2025 Ex-Date- 4/15/2025 Record- 4/15/2025 Payable- 5/1/2025 Ticker Distribution Change From Prior Distribution BlackRock Municipal Income Quality Trust* BYM $0.055500 - BlackRock Long-Term Municipal Advantage Trust* BTA $0.049500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Trust* BFK $0.050000 - BlackRock Investment Quality Municipal Trust, Inc.* BKN $0.057000 - BlackRock Municip
Today, BlackRock Resources & Commodities Strategy Trust (NYSE:BCX), BlackRock Enhanced Equity Dividend Trust (NYSE:BDJ), BlackRock Energy and Resources Trust (NYSE:BGR), BlackRock Enhanced International Dividend Trust (NYSE:BGY), BlackRock Health Sciences Trust (NYSE:BME), BlackRock Health Sciences Term Trust (NYSE:BMEZ), BlackRock Enhanced Global Dividend Trust (NYSE:BOE), BlackRock Utilities, Infrastructure & Power Opportunities Trust (NYSE:BUI), BlackRock Enhanced Large Cap Core Fund, Inc. (NYSE:CII), BlackRock Science and Technology Trust (NYSE:BST), BlackRock Science and Technology Term Trust (NYSE:BSTZ), BlackRock Technology and Private Equity Term Trust (NYSE:BTX), BlackRock Capital
Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: National Funds Ticker Distribution Declaration- 3/3/2025 Ex-Date- 3/14/2025 Record- 3/14/2025 Payable- 4/1/2025 Ticker Distribution Change From Prior Distribution BlackRock Municipal Income Quality Trust* BYM $0.055500 - BlackRock Long-Term Municipal Advantage Trust* BTA $0.049500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Trust* BFK $0.050000 - BlackRock
Today, BlackRock Resources & Commodities Strategy Trust (NYSE:BCX), BlackRock Enhanced Equity Dividend Trust (NYSE:BDJ), BlackRock Energy and Resources Trust (NYSE:BGR), BlackRock Enhanced International Dividend Trust (NYSE:BGY), BlackRock Health Sciences Trust (NYSE:BME), BlackRock Health Sciences Term Trust (NYSE:BMEZ), BlackRock Enhanced Global Dividend Trust (NYSE:BOE), BlackRock Utilities, Infrastructure & Power Opportunities Trust (NYSE:BUI), BlackRock Enhanced Large Cap Core Fund, Inc. (NYSE:CII), BlackRock Science and Technology Trust (NYSE:BST), BlackRock Science and Technology Term Trust (NYSE:BSTZ), BlackRock Technology and Private Equity Term Trust (NYSE:BTX), BlackRock Capital
The BlackRock closed-end funds listed below (each, a "Fund" and collectively, the "Funds") announced today the renewal of their discount management programs (each, a "Program" and collectively, the "Programs"). Under the terms of each Fund's Program, each Fund intends to offer to repurchase a portion of its common shares via tender offer if certain conditions are met during the specified time period, as detailed below. BlackRock Closed-End Funds Renewing their Discount Management Programs Fund Name Ticker BlackRock Capital Allocation Term Trust BCAT BlackRock ESG Capital Allocation Term Trust ECAT BlackRock Science and Technology Term Tr
SAN DIEGO, April 15, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced financial results for the fourth quarter and year ended December 31, 2021. Financial and corporate highlights for the quarter and year months ended December 31, 2021 and subsequently include the following: Fourth quarter ended December 31, 2021: Appointed Susan McClatchey as Vice President and Head of QualityNamed to both the Nasdaq Biotechnology Index and the ICE Biotechnology Ind
NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced financial results for the quarter ended September 30, 2021. Financial and corporate highlights for the quarter ended September 30, 2021 and subsequently include the following: Transitioned from the NYSE American to the Nasdaq Global Market to better align with industry peersCompleted the acquisition of Novellus TherapeuticsAppointed Roger Sidhu, M.D. as chief medical officer, Jay Sial
NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today provided highlights from a Shareholder Update Call conducted on September 20, 2021 by President and Chief Executive Officer Howard J. Federoff, M.D., Ph.D., with guest contributor Matt Angel, Ph.D., Factor Bioscience's Co-founder and Chief Executive Officer. The call was based on Brooklyn's most recent corporate slide deck, which can be found here. Highlights of the call included: Brooklyn